179 related articles for article (PubMed ID: 6816189)
1. Therapeutical pseudomonas aeruginosa antisera. Preparation, control and administration.
Meitert T; Meitert E; Szegli G; Peligrad I
Arch Roum Pathol Exp Microbiol; 1982; 41(2):115-21. PubMed ID: 6816189
[No Abstract] [Full Text] [Related]
2. Mono--and polyvalent Pseudomonas aeruginosa vaccines. Preparation, control and administration.
Meitert E; Meitert T; Sima F; Savulian C
Arch Roum Pathol Exp Microbiol; 1982; 41(2):105-14. PubMed ID: 6816188
[No Abstract] [Full Text] [Related]
3. Investigations on the efficacy of monovalent Pseudomonas aeruginosa vaccine for oral administration in Pseudomonas aeruginosa experimental infection.
Meitert E; Sima F; Savulian C; Petrovici M; Chersulick E; Costache G
Arch Roum Pathol Exp Microbiol; 1989; 48(3):237-51. PubMed ID: 2519634
[TBL] [Abstract][Full Text] [Related]
4. [Development of immunological preparations and their use for preventing and treating pyocyanic infection in burn patients].
Kolker II; Stanislavskiĭ ES; Grishina IA; Panova IuM; Krokhina MA
Probl Gematol Pereliv Krovi; 1981 Jan; 26(1):29-33. PubMed ID: 6784114
[No Abstract] [Full Text] [Related]
5. Efficiency of Pseudomonas aeruginosa vaccines in the prevention and treatment of Pseudomonas infections in burned patients.
Ionescu A; Meitert E; Vasiliu S; Meitert T; Sima F; Savulian C; Milicescu S
Arch Roum Pathol Exp Microbiol; 1981; 40(4):323-32. PubMed ID: 6803737
[No Abstract] [Full Text] [Related]
6. Use of passive immunotherapy in the treatment of experimental Pseudomonas aeruginosa infections in burns.
Neely AN; Holder IA
Antibiot Chemother (1971); 1987; 39():26-40. PubMed ID: 3118788
[No Abstract] [Full Text] [Related]
7. The immunoprophylaxis and immunotherapy of Pseudomonas infections in burns with polyvalent Pseudomonas aeruginosa corpuscular vaccine.
Ionescu A; Meitert E; Vasiliu S; Meitert T; Milicescu S; Sima F; Savulian C
Arch Roum Pathol Exp Microbiol; 1979; 38(3-4):317-30. PubMed ID: 122594
[No Abstract] [Full Text] [Related]
8. Investigations on the efficacy of specific immunization with corpuscular vaccines in urinary tract infections with Pseudomonas aeruginosa or mixed bacteria.
Neagu V; Meitert E; Ioanid CP; Racovită C; Găleşanu M; Sima F; Savulian C; Momiceanu D; Noica N; Neagoe M
Arch Roum Pathol Exp Microbiol; 1984; 43(1):39-52. PubMed ID: 6442131
[No Abstract] [Full Text] [Related]
9. Anti-Pseudomonas immunoglobulin. III. Preliminary clinical evaluation.
Sakiel S; Schiller B; Buchowicz I; Kotkowska-Tomanek E
Arch Immunol Ther Exp (Warsz); 1983; 31(4):517-21. PubMed ID: 6422901
[TBL] [Abstract][Full Text] [Related]
10. [Infection and host responses. (6) Evaluation of Pseudomonas vaccine therapy in refractory infection of the respiratory and transit areas].
Tanimoto H; Tachibana A
Nihon Naika Gakkai Zasshi; 1982 Oct; 71(10):1384-8. PubMed ID: 6820039
[No Abstract] [Full Text] [Related]
11. Study of Pseudomonas haemolysin. III. Properties of antilysin serum.
Lochmann O; Výmola F
J Hyg Epidemiol Microbiol Immunol; 1975; 19(2):224-9. PubMed ID: 809503
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy with monovalent Pseudomonas aeruginosa vaccine in chronic respiratory infections.
Popescu C; Meitert E; Rusu R; Meitert T; Sima F; Savulian C
Arch Roum Pathol Exp Microbiol; 1982; 41(3):265-76. PubMed ID: 6818929
[No Abstract] [Full Text] [Related]
13. [Donor plasma with anti-Pseudomonas aeruginosa activity as a directed-action preparation].
Nazarchuk LV
Vrach Delo; 1987 Jul; (7):96-8. PubMed ID: 3114958
[No Abstract] [Full Text] [Related]
14. Development of an anti-adhesive vaccine for Pseudomonas aeruginosa targeting the C-terminal region of the pilin structural protein.
Sheth HB; Glasier LM; Ellert NW; Cachia P; Kohn W; Lee KK; Paranchych W; Hodges RS; Irvin RT
Biomed Pept Proteins Nucleic Acids; 1995; 1(3):141-8. PubMed ID: 9346845
[TBL] [Abstract][Full Text] [Related]
15. [Evaluation of the specific activity of hyperimmune anti-Pseudomonas aeruginosa human plasma in an experiment].
Podgornaia LG; Shinkarenko AA; Krokhina MA; Dziuban NF; D'iachenko VF
Patol Fiziol Eksp Ter; 1987; (2):70-2. PubMed ID: 3112715
[No Abstract] [Full Text] [Related]
16. Investigation on the therapeutical efficiency of some adapted bacteriophages in experimental infection with Pseudomonas aeruginosa.
Meitert E; Petrovici M; Sima F; Costache G; Savulian C
Arch Roum Pathol Exp Microbiol; 1987; 46(1):17-26. PubMed ID: 3124795
[No Abstract] [Full Text] [Related]
17. [Protective effect of Pseudomonas-specific immunoglobulin from the rabbit and of active immunization in experimental Pseudomonas sepsis in mice].
Trautmann M; Brückner O; Hahn H
Zentralbl Bakteriol Mikrobiol Hyg A Med Mikrobiol Infekt Parasitol; 1982 Jul; 252(3):370-83. PubMed ID: 6215803
[TBL] [Abstract][Full Text] [Related]
18. [Our experience with the treatment of burns with sheep serum against Pseudomonas aeruginosa].
Orłowski T; Struzyna J; Badowski A; Schiller B; Kuntze A; Kozaczek W; Goller W
Wiad Lek; 1980 Nov; 33(21):1697-701. PubMed ID: 6784349
[No Abstract] [Full Text] [Related]
19. Multi-valent human monoclonal antibody preparation against Pseudomonas aeruginosa derived from transgenic mice containing human immunoglobulin loci is protective against fatal pseudomonas sepsis caused by multiple serotypes.
Lai Z; Kimmel R; Petersen S; Thomas S; Pier G; Bezabeh B; Luo R; Schreiber JR
Vaccine; 2005 May; 23(25):3264-71. PubMed ID: 15837231
[TBL] [Abstract][Full Text] [Related]
20. Vaccines against Pseudomonas aeruginosa infection: 2. Clinico-immunological investigations.
Krokhina MA; Grishina IA; Panova YuM ; Terekhova RP; Severtsova MK; Yedvabnaya LS; Vaide M; Varro R; Rusanov VM; Kolker II
Vaccine; 1985 Sep; 3(3):316-24. PubMed ID: 3933202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
